Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inboxGmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscriptionClick this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
Bonus Article from MarketBeat
A Dividend King on Sale: Is Abbott Labs a Healthcare Bargain?Reported by Jeffrey Neal Johnson. Posted: 4/7/2026. 
Key Points
- Abbott's Medical Devices division continues to accelerate, demonstrating the underlying strength within the company's largest business segment.
- Abbott's impressive history of consecutive dividend increases underscores its commitment to consistently rewarding long-term shareholders.
- Strategic acquisitions are positioning Abbott to lead in new high-growth healthcare sectors, securing a powerful pipeline for future expansion.
- Special Report: Have $500? Invest in Elon’s AI Masterplan
In the world of investing, stability is a prized commodity. Few companies embody that stability better than Abbott Laboratories (NYSE: ABT), a diversified healthcare powerhouse and a member of the elite dividend kings. For decades investors have relied on Abbott for steady growth and dependable income. That long-standing reputation makes its recent performance all the more striking.
For a moment…
Forget about Trump’s ties to Israel.
Forget about reports of Iran’s nuclear program.
Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason. Click here to find out what it is.
Abbott Laboratories’ stock price recently touched a 52-week low, closing just above $100 in the final trading days of March. The decline has raised questions about whether the foundation of this industry leader is cracking. A closer look at Abbott’s situation suggests a potential disconnect between market sentiment and operational reality. The key question for investors is whether today's pessimism is justified or if a meaningful value opportunity has emerged for those with a long-term horizon. Separating the Signal From the NoiseA stock like Abbott doesn't fall without reason, and its recent slide reflects two distinct pressures. The first is an internal headwind from its Nutrition segment. Abbott Laboratories’ fourth-quarter 2025 earnings report showed a 9.1% organic sales decline in this division, driven mainly by market-share losses in its U.S. pediatric business and pricing dynamics that constrained volume. Management has acknowledged the challenge and outlined a clear turnaround plan. CEO Robert B. Ford detailed price and promotion initiatives plus a pipeline of at least eight new product launches in 2026, forecasting a return to growth in the second half of the year. The second factor is external and broader in scope: a rotation of capital across the market. During periods of economic optimism, investors frequently shift funds out of defensive sectors like the healthcare sector and into higher-beta areas such as artificial intelligence (AI) and the energy sector in search of faster returns. That broad trend has weighed on many fundamentally sound healthcare names, Abbott included, pressuring stock prices for reasons largely unrelated to company-level performance or long-term prospects. Abbott’s Engine Room Is Running StrongWhile Nutrition works through a short-term recovery, Abbott's core remains robust, led by its largest and most profitable division: Medical Devices. That segment is accelerating, posting 10.4% organic growth in the most recent quarter. Abbott's diversified model helps offset isolated weakness in Nutrition, and the company’s strongest businesses show the health of the franchise.
Medical Devices: The Medical Devices segment is firing on multiple cylinders, driven by market-leading innovation in critical care areas. Diabetes Care: The FreeStyle Libre franchise of continuous glucose monitors (CGM) remains a major growth engine. This product line, which lets users track glucose without routine fingersticks, generated more than $7.5 billion in sales in 2025 and is a key contributor to Abbott's sustained success. Cardiovascular Leadership: Abbott is a dominant player in cardiovascular health. Its Electrophysiology business grew at a double-digit pace, and Structural Heart posted strong organic growth of 8.7%. That performance is supported by a portfolio of best-in-class products such as MitraClip and TriClip, which offer minimally invasive valve repair, and by a pipeline of innovations including the recently FDA-approved Volt PFA System for treating atrial fibrillation. Abbott is also positioning itself for future growth beyond its existing portfolio through the acquisition of Exact Sciences. Exact Sciences is a leader in cancer screening and diagnostics, best known for its non-invasive colon cancer test, Cologuard. The deal would immediately strengthen Abbott's position in the expanding, multi-billion-dollar cancer diagnostics market, adding a high-growth vertical that could contribute materially to revenue over time. That bullish view is shared by analysts. Wall Street maintains a Moderate Buy consensus rating on the stock, and the average 12-month price target of $135.47 implies upside of more than 30% from current levels — a signal that many professionals see the shares as undervalued. A Bedrock of Reliability for Income InvestorsFor long-term investors, especially those focused on income, Abbott’s dividend is a compelling feature. Abbott is a member of the S&P 500 Dividend Kings, an exclusive group of companies that have increased their dividend for at least 50 consecutive years. That track record demonstrates a strong commitment to returning capital to shareholders through all market cycles. The recent drop in Abbott’s stock price benefits new income investors by boosting the dividend yield. At current prices, Abbott yields roughly 2.5%, allowing investors to lock in a higher income rate from a historically reliable payer. The dividend appears secure: the payout ratio is about 68% of earnings and represents only about 37% of cash flow, indicating ample cash generation to cover the dividend and room for future increases. A Disconnect Between Price and ValueCurrent market sentiment toward Abbott appears disconnected from the company's underlying business fundamentals. Temporary headwinds in one division and broader market rotations have depressed the stock price, even as Abbott's core growth engines accelerate. Its dominant Medical Devices business continues to deliver, the dividend remains a reliable anchor for income investors, and catalysts like the Exact Sciences acquisition could add long-term growth. For investors with a multi-year perspective, the present valuation suggests a notable gap between price and intrinsic value — an opportunity worth considering. |
